http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2023, Vol. 32 ›› Issue (5): 417-425.DOI: 10.5246/jcps.2023.05.035

• Drug administration and clinical pharmacy column • Previous Articles     Next Articles

Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method

Min Wan1, Jinyu Liu2, Guangyi Yu1, Suiju Tong1, Lei Ke3, Yu Zhang3, Ruxu You3,*()   

  1. 1 Department of Pharmacy, People’s Hospital of Dongxihu District, Wuhan 430040, Hubei, China
    2 Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China
    3 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China
  • Received:2022-09-06 Revised:2022-11-29 Accepted:2022-12-08 Online:2023-06-02 Published:2023-06-02
  • Contact: Ruxu You

Abstract:

In the present study, we aimed to investigate the availability and affordability of osteoporosis (OP) treatment drugs in Wuhan and provide references for policymakers. We used the WHO/HAI standardization method to investigate the OP drug in Wuhan and collected drug information for statistical analysis to evaluate the availability and affordability. The results showed that the availability of bisphosphonates, active vitamin D, and their analogs was relatively high; the availability of denosumab, salmon calcitonin, and teriparatide was general; and the availability of calcitonin, raloxifene, and strontium ranelate was low. In terms of affordability, alendronate generic drugs had good affordability, while the other 10 OP treatment drugs had poor affordability. Generally, the overall availability of OP treatment drugs in Wuhan was average, and the affordability was poor. As China’s aging problem intensified, relevant government departments might consider including more OP treatment drugs in the medical insurance catalog and concentrating their quantities in the procurement process to further improve the availability and affordability of OP treatment drugs.

Key words: WHO/HAI, Osteoporosis treatment drugs, Availability, Affordability

Supporting: